The Joint Detection Research Of HMGB1 And PSA In The Diagnosis Of Prostatic Cancer

Background Prostate cancer is a common malignant tumor in elderly male urogenital system and the incidence in China is trending to rapidly ascend in recent years. The incidence of prostate cancer in China has increased nearly three times as much, rose from 1.1/1 hundred thousand in 1990 to 4.3/1 hundred thousand in 2008 according to epidemiological investigation data, is expected to reach 6.3/1 hundred thousand in 2020.PSA(prostate-specific antigen) is the marker for early discovery and detection of prostatic cancer, but due to the lack of specificity, misdiagnosis might be possible. The expression of HMGB1 in prostatic cancer is high. HMGB1 is associated with the growth, invasion and metastasis of prostatic cancer. The joint detection of the two markers will contribute to the early diagnosis of prostatic cancer.Objective The expression of HMGB1 and PSA in BPH (benign prostatic hyperplasia) and prostatic cancer and their difference were detected to reveal the correlation between the two; the relationship between the joint detection of HMGB1 and PSA and prostatic cancer was discussed to provide experimental basis for revealing certain auxiliary diagnosis of HGMB1 to prostatic cancer.Method Collected blood serum of prostate disease patients confirmed by transrectal prostate biopsy pathology examination or postoperative pathology in No.371 Hospital of PLA and Xinxiang central hospital from 2012 to 2014:prostatic cancer group 37 cases, BPH group 34 cases and the control group 30 cases. In order to control the factors affecting the serum level of HMGB1 and PSA, select patients in strict accordance with the following standards:1. Patients aged more than 50; 2. Exclude hepatitis B patients; 3. No prostate massage, transrectal prostate B ultrasonic examination and prostate biopsy are performed before PSA determination; 4. Patients without acute chronic prostatitis; 5. Exclude patients of acute urinary retention; 6. Blood of all patients is drawn by the biochemical tube for about 5ml, centrifugal separated timely and put in -70degrees ultra cold storage freezer. Analyze the expression difference of HMGB1 and PSA in prostatic cancer serum and BPH serum; The correlation of the expression of HMGB1 and PSA in prostatic cancer serum was analyzed by Spearman correlation test.Result1.Differences of serum HMGB1 level between the three groups were statistically significant (P<0.001).There were significant differences of serum PSA between Pca group and BPH group, healthy group(.P<0.001). Difference between BPH group and health group was statistically significant (P=0.028).2.In 37 cases of Pca patients, among which 8 cases have proved invasion or distant metastasis,6 cases were in phase C:the tumor had infiltrated or beyond the prostate capsule.2 patients were in phase D, MRI and whole body bone imaging showed pelvic lymph node and distant metastasis. The difference of serum HMGB1 between 29 patients in phase A and B and 8 petients in phase C and D was statistically significant(t=3.13, .P=0.001). The intergroup difference of HMGB1 between phase C and phase D was statistically significant (P<0.01).3.The single sensitivity and specificity of HMGB1 were 83% and 75%, while which of PSA were 67% and 82%. The sensitivity reached to 90%, specificity to 61%, accuracy to 80% when the two jointed.Conclusion The joint detection of HMGB1 and PSA could improve the diagnostic efficiency of prostatic cancer.